Abstract:Renal fibrosis is a characteristic of progressive renal diseases leading to end‐stage renal failure. Induction of renal fibrosis via the mouse unilateral ureteral occlusion (UUO) model occurs within 5 days making it a high throughput model to evaluate novel therapeutic targets. Transforming growth factor‐beta (TGF‐β) is a key signaling molecule in the pathogenesis of renal fibrosis mediated through its actions on its receptor, Activin A Receptor‐Like Kinase (ALK5). Previously, we have shown the anti‐TGF‐β antibody (1D11; clone 1D11.16.8) attenuates UUO‐induced renal fibrosis. Here, we evaluated and compared the dose‐dependent ability of an orally‐available ALK5 inhibitor (SB‐525334) to attenuate UUO‐induced tissue biomarkers. To minimize the number of necessary control groups and ensure all mice were handled similarly, all mice received intraperitoneal injections of PBS or 3 mg/kg 1D11 QD d‐1 through d4 and oral gavage administration of vehicle or SB‐525334 (10, 30 or 100 mg/kg) QD d‐1 through d5. On d0, mice (male, CD‐1, 8–9 weeks age) underwent sham (n=8) or permanent total ligation of the right ureter (UUO, n=12–13/group) via aseptic laparotomy. Five days post‐UUO or sham surgery, renal tissue from sham or obstructed kidney was collected for analysis of profibrotic mRNA biomarker expression, TGF‐β content, hydroxyproline content and renal fibrosis as expressed as collagen volume fraction (CVF; quantitated via histological image analysis of Picrosirius Red stained mid‐transverse kidney sections). Consistent with a pathophysiological response to ureteral obstruction, UUO reliably (100%) elicited hydronephrosis. UUO increased renal cortical mRNA expression of several fibrotic markers—fibronectin‐1 (FN‐1; 3.4±0.5 fold induction from sham), alpha‐smooth muscle actin (α‐SMA; 0.9±0.2 fold), collagen 1A1 (Col1A1; 12.7±4.2 fold) and collagen 3A1 (Col3A1; 5.8±0.8 fold) as well as increased renal cortical TGF‐β content (2.8±0.2 fold), hydroxyproline content (1.6±0.1 fold) and CVF (8.8±0.9 fold). 1D11 attenuated UUO‐induced increases in FN‐1 (45.5±5.6%), Col1A1 (61.3±9.6%) and Col3A1 (48.6±8.2%) mRNA expression, TGF‐β content (38.8±5.9% inhibition), hydroxyproline content (23.4±6.5%), and CVF (42.6±5.7%). High dose (100 mg/kg) SB‐525334 attenuated UUO‐induced increases in FN‐1 (77.8 ±6.4%), α‐SMA (111.0±23.6%), Col1A1 (77.1±4.1%) and Col3A1 (56.0±7.8%) mRNA expression, as well as TGF‐β content (35.2±6.3%), hydroxyproline content (46.5±4.4%), and CVF (73.7±4.8% inhibition). The current data demonstrate the importance of TGF‐β signaling in fibrotic consequences of ureteral obstruction. Additionally, UUO‐induced renal injury can be modulated by a parenterally administered biological agent (1D11) as well as by an orally administered small molecule (SB‐525334) thus eliminating the need for multiple dosing routes in future UUO studies where a reference agent is utilized.

CH6824025, Potent and Selective Discoidin Domain Receptor 1 Inhibitor, Reduces Kidney Fibrosis in Unilateral Ureteral Obstruction Mice

Inhibition Of Class I Hdacs Attenuates Renal Interstitial Fibrosis In A Murine Model

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction.

Selective Inhibition of Class IIa Histone Deacetylases Alleviates Renal Fibrosis

Effects of Transforming Growth Factor‐Beta (TGF‐β) Receptor I Inhibition on Renal Biomarkers and Fibrosis in Unilateral Ureteral Occluded (UUO) Mice.

Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction

Dual soluble epoxide hydrolase inhibitor – farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis

Inhibition of Src kinase can ameliorate renal interstitial fibrosis in unilateral ureteral obstruction mice

Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis

Huangqi-Danshen Decoction Against Renal Fibrosis in UUO Mice via TGF-β1 Induced Downstream Signaling Pathway

Atorvastatin reduces renal interstitial fibrosis caused by unilateral ureteral obstruction through inhibiting the transcriptional activity of YAP

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation.

Genetic or Sirna Inhibition of MBD2 Attenuates the UUO- and I/R-induced Renal Fibrosis Via Downregulation of EGR1

Vildagliptin Treatment Ameliorates Renal Interstitial Fibrosis in a Murine Model of Unilateral Ureteral Obstruction

Resveratrol Inhibits Epithelial-Mesenchymal Transition and Renal Fibrosis by Antagonizing the Hedgehog Signaling Pathway

Glycolysis Inhibitors Suppress Renal Interstitial Fibrosis Via Divergent Effects on Fibroblasts and Tubular Cells.

Renoprotection of Microcystin-RR in Unilateral Ureteral Obstruction-Induced Renal Fibrosis: Targeting the PKM2-HIF-1α Pathway

Research progress of DDR1 inhibitors in the treatment of multiple human diseases

Inhibition Effect of AcSDKP on Unilateral Ureteral Obstruction-induced Renal Interstitial Fibrosis in Rats

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Attenuates Renal Inflammation And Tubulointerstitial Fibrosis In Rats